Novel prognostic molecular markers in lung cancer (Review)
- Authors:
- Michał Puderecki
- Justyna Szumiło
- Barbara Marzec‑Kotarska
-
Affiliations: Department of Clinical Pathomorphology, The Medical University of Lublin, 20‑090 Lublin, Poland - Published online on: April 15, 2020 https://doi.org/10.3892/ol.2020.11541
- Pages: 9-18
This article is mentioned in:
Abstract
|
Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pardo J, Martinez-Peñuela AM, Sola JJ, Panizo A, Gúrpide A, Martinez-Peñuela JM and Lozano MD: Large cell carcinoma of the lung: An endangered species? Appl Immunohistochem Mol Morphol. 17:383–392. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tomasetti C, Marchionni L, Nowak MA, Parmigiani G and Vogelstein B: Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci USA. 112:118–123. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Taylor CR, Shi SR, Barr NJ and Wu N: Techniques of immunohistochemistry: Principles, pitfalls and standardization. Diagnostic Immunohistochemistry (Second). 1–42. 2006. View Article : Google Scholar | |
|
Jin BF, Yang F, Ying XM, Gong L, Hu SF, Zhao Q, Liao YD, Chen KZ, Li T, Tai YH, et al: Signaling protein signature predicts clinical outcome of non-small-cell lung cancer. BMC Cancer. 18:2592018. View Article : Google Scholar : PubMed/NCBI | |
|
Gu Z, Fang X, Li C, Chen C, Liang G, Zheng X and Fan Q: Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer. Int J Oncol. 51:489–497. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Phelps CA, Lai SC and Mu D: Roles of thyroid transcription factor 1 in lung cancer biology. Vitam Horm. 106:517–544. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Takahashi H, Ogata H, Nishigaki R, Broide DH and Karin M: Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell. 17:89–97. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao C, Li X, Su C, Li J, Cheng N, Ren S, Chen X and Zhou C: High expression of E-cadherin in pleural effusion cells predicts better prognosis in lung adenocarcinoma patients. Int J Clin Exp Pathol. 8:3104–3109. 2015.PubMed/NCBI | |
|
Min J, Huang K, Tang H, Ding X, Qi C, Qin X and Xu Z: Phloretin induces apoptosis of non-small cell lung carcinoma A549 cells via JNK1/2 and p38 MAPK pathways. Oncol Rep. 34:2871–2879. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang LN, Wang DS, Chen YQ, Li W, Hu FD, Gong BL, Zhao CL and Jia W: Meta-analysis for cyclin E in lung cancer survival. Clin Chim Acta. 413:663–668. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rao G, Pierobon M, Kim IK, Hsu WH, Deng J, Moon YW, Petricoin EF, Zhang YW, Wang Y and Giaccone G: Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Sci Rep. 7:70662017. View Article : Google Scholar : PubMed/NCBI | |
|
Correia LL, Johnson JA, McErlean P, Bauer J, Farah H, Rassl DM, Rintoul RC, Sethi T, Lavender P, Rawlins EL, et al: SOX2 drives bronchial dysplasia in a novel organotypic model of early human squamous lung cancer. Am J Respir Crit Care Med. 195:1494–1508. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Z, Yang F, Zhang Y, Wang X, Shi J, Wei H, Sun F and Yu Y: Girdin protein: A potential metastasis predictor associated with prognosis in lung cancer. Exp Ther Med. 15:2837–2843. 2018.PubMed/NCBI | |
|
Wan T, Shao J, Hu B, Liu G, Luo P and Zhou Y: Prognostic role of HSF1 overexpression in solid tumors: A pooled analysis of 3,159 patients. Onco Targets Ther. 11:383–393. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tsukao Y, Yamasaki M, Miyazaki Y, Makino T, Takahashi T, Kurokawa Y, Miyata H, Nakajima K, Takiguchi S, Mimori K, et al: Overexpression of heat-shock factor 1 is associated with a poor prognosis in esophageal squamous cell carcinoma. Oncol Lett. 13:1819–1825. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gökmen-Polar Y and Badve S: Upregulation of HSF1 in estrogen receptor positive breast cancer. Oncotarget. 7:84239–84245. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chuma M, Sakamoto N, Nakai A, Hige S, Nakanishi M, Natsuizaka M, Suda G, Sho T, Hatanaka K, Matsuno Y, et al: Heat shock factor 1 accelerates hepatocellular carcinoma development by activating nuclear factor-κB/mitogen-activated protein kinase. Carcinogenesis. 35:272–281. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
White GE, Tan TC, John AE, Whatling C, McPheat WL and Greaves DR: Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res. 85:825–835. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H and Mori M: The high expression of fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol. 26:41–47. 2005.PubMed/NCBI | |
|
Hyakudomi M, Matsubara T, Hyakudomi R, Yamamoto T, Kinugasa S, Yamanoi A, Maruyama R and Tanaka T: Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol. 15:1775–1782. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Park MH, Lee JS and Yoon JH: High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J Surg Oncol. 106:386–392. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Su YC, Chang H, Sun SJ, Liao CY, Wang LY, Ko JL and Chang JT: Differential impact of CX3CL1 on lung cancer prognosis in smokers and non-smokers. Mol Carcinog. 57:629–639. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Folescu R, Levai CM, Grigoraş ML, Arghirescu TS, Talpoş IC, Gîndac CM, Zamfir CL, Poroch V and Anghel MD: Expression and significance of Ki-67 in lung cancer. Rom J Morphol Embryol. 59:227–233. 2018.PubMed/NCBI | |
|
Villa E, Proïcs E, Rubio-Patiño C, Obba S, Zunino B, Bossowski JP, Rozier RM, Chiche J, Mondragón L, Riley JS, et al: Parkin-independent mitophagy controls chemotherapeutic response in cancer cells. Cell Rep. 20:2846–2859. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang R, Gu J, Chen J, Ni J, Hung J, Wang Z, Zhang X, Feng J and Ji L: High expression of PINK1 promotes proliferation and chemoresistance of NSCLC. Oncol Rep. 37:2137–2146. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chang G, Zhang W, Ma Y and Wen Q: PINK1 expression is associated with poor prognosis in lung adenocarcinoma. Tohoku J Exp Med. 245:115–121. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chuang CY, Chen MK, Hsieh MJ, Yeh CM, Lin CW, Yang WE, Yang SF and Chou YE: High level of plasma EGFL6 is associated with clinicopathological characteristics in patients with oral squamous cell carcinoma. Int J Med Sci. 14:419–424. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bai S, Ingram P, Chen YC, Deng N, Pearson A, Niknafs YS, O'Hayer P, Wang Y, Zhang ZY, Boscolo E, et al: EGFL6 regulates the asymmetric division, maintenance, and metastasis of ALDH+ ovarian cancer cells. Cancer Res. 76:6396–6409. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chang CC, Sung WW, Hsu HT, Yeh CM, Lee CH, Chen YL, Liu TC and Yeh KT: Validation of EGFL6 expression as a prognostic marker in patients with lung adenocarcinoma in Taiwan: A retrospective study. BMJ Open. 8:e0213852018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Qiao WB and Shan L: Expression and functional characterization of FOXM1 in non-small cell lung cancer. Onco Targets Ther. 11:3385–3393. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Q, Dong M, Chen Y, Zhang J, Qiao J and Guo X: Prognostic significance of FoxM1 expression in non-small cell lung cancer. J Thorac Dis. 8:1269–1273. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MS, Kim E, Heo JS, Bae DJ, Lee JU, Lee TH, Lee HJ, Chang HS, Park JS, Jang AS, et al: Circulating IL-33 level is associated with the progression of lung cancer. Lung Cancer. 90:346–351. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang M, Feng Y, Yue C, Xu B, Chen L, Jiang J, Lu B and Zhu Y: Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. PLoS One. 13:e01934282018. View Article : Google Scholar : PubMed/NCBI | |
|
Deng Y, Ge P, Tian T, Dai C, Wang M, Lin S, Liu K, Zheng Y, Xu P, Zhou L, et al: Prognostic value of flotillins (flotillin-1 and flotillin-2) in human cancers: A meta-analysis. Clin Chim Acta. 481:90–98. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang YL, Yao WJ, Guo L, Xi HF, Li SY and Wang ZM: Expression of flotillin-2 in human non-small cell lung cancer and its correlation with tumor progression and patient survival. Int J Clin Exp Pathol. 8:601–607. 2015.PubMed/NCBI | |
|
Wen Q, Wang W, Chu S, Luo J, Chen L, Xie G, Xu L, Li M and Fan S: Flot-2 expression correlates with EGFR levels and poor prognosis in surgically resected non-small cell lung cancer. PLoS One. 10:e01321902015. View Article : Google Scholar : PubMed/NCBI | |
|
Feng C, Feng M, Gao Y, Zhao X, Peng C, Yang X and Zhang J: Clinicopathologic significance of intestinal-type molecules' expression and different EGFR gene status in pulmonary adenocarcinoma. Appl Immunohistochem Mol Morphol. Feb 27–2018.(Epub ahead of print). PubMed/NCBI | |
|
Litan A and Langhans SA: Cancer as a channelopathy: Ion channels and pumps in tumor development and progression. Front Cell Neurosci. 9:862015. View Article : Google Scholar : PubMed/NCBI | |
|
Prevarskaya N, Skryma R and Shuba Y: Ion channels and the hallmarks of cancer. Trends Mol Med. 16:107–121. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Suo A, Childers A, D'Silva A, Petersen LF, Otsuka S, Dean M, Li H, Enwere EK, Pohorelic B, Klimowicz A, et al: Cav3.1 overexpression is associated with negative characteristics and prognosis in non-small cell lung cancer. Oncotarget. 9:8573–8583. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou H, Cai L, Zhang X, Li A, Miao Y, Li Q, Qiu X and Wang E: ARHGEF39 promotes tumor progression via activation of Rac1/P38 MAPK/ATF2 signaling and predicts poor prognosis in non-small cell lung cancer patients. Lab Invest. 98:670–681. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Q, Chen Y, Feng H, Zhang B and Wang H: Prognostic and predictive value of HURP in non-small cell lung cancer. Oncol Rep. 39:1682–1692. 2018.PubMed/NCBI | |
|
Hu G and Wang S: Prognostic role of tumor-infiltrating CD57-positive lymphocytes in solid tumors: A meta-analysis. Oncotarget. 9:8111–8119. 2017.PubMed/NCBI | |
|
Nielsen CM, White MJ, Goodier MR and Riley EM: Functional significance of CD57 expression on human NK cells and relevance to disease. Front Immunol. 4:4222013. View Article : Google Scholar : PubMed/NCBI | |
|
Badalamenti G, Fanale D, Incorvaia L, Barraco N, Listì A, Maragliano R, Vincenzi B, Calò V, Iovanna JL, Bazan V and Russo A: Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? Cell Immunol. 343:1037532019. View Article : Google Scholar : PubMed/NCBI | |
|
Peng Y and Croce CM: The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 1:150042016. View Article : Google Scholar : PubMed/NCBI | |
|
Dong Y and Qiu GB: Biological functions of miR-590 and its role in carcinogenesis. Front Lab Med. 1:173–176. 2017. View Article : Google Scholar | |
|
Ma Z, Wang Y, He B, Cui J, Zhang C, Wang H, Feng W, Wang B, Wei D, Wu Y, et al: Expression of miR-590 in lung cancer and its correlation with prognosis. Oncol Lett. 15:1753–1757. 2018.PubMed/NCBI | |
|
Testa U, Pelosi E, Castelli G and Labbaye C: miR-146 and miR-155: Two key modulators of immune response and tumor development. Noncoding RNA. 3(pii): E222017.PubMed/NCBI | |
|
Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Sun Y and Liu Q: MicroRNA-340 induces apoptosis and inhibits metastasis of ovarian cancer cells by inactivation of NF-κB1. Cell Physiol Biochem. 38:1915–1927. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Qin Y, Zhou X, Huang C, Li L, Liu H, Liang N, Chen Y, Ma D, Han Z, Xu X, et al: Lower miR-340 expression predicts poor prognosis of non-small cell lung cancer and promotes cell proliferation by targeting CDK4. Gene. 675:278–284. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ghoshal-Gupta S, Kutiyanawalla A, Lee BR, Ojha J, Nurani A, Mondal AK, Kolhe R, Rojiani AM and Rojiani MV: TIMP-1 downregulation modulates miR-125a-5p expression and triggers the apoptotic pathway. Oncotarget. 9:8941–8956. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu WY, Luo B, An JY, He JY, Chen DD, Xu LY, Huang YY, Liu XG, Le HB and Zhang YK: Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer. Cancer Invest. 32:394–401. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Faversani A, Amatori S, Augello C, Colombo F, Porretti L, Fanelli M, Ferrero S, Palleschi A, Pelicci PG, Belloni E, et al: miR-494-3p is a novel tumor driver of lung carcinogenesis. Oncotarget. 8:7231–7247. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Min L, Ren C, Xu X, Yang J, Sun X, Wang T, Wang F, Sun C and Zhang X: MiRNA-148a serves as a prognostic factor and suppresses migration and invasion through Wnt1 in non-small cell lung cancer. PLoS One. 12:e01717512017. View Article : Google Scholar : PubMed/NCBI | |
|
Bach DH, Lee SK and Sood AK: Circular RNAs in cancer. Mol Ther Nucleic Acids. 16:118–129. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ding L, Yao W, Lu J, Gong J and Zhang X: Upregulation of circ_001569 predicts poor prognosis and promotes cell proliferation in non-small cell lung cancer by regulating the Wnt/β-catenin pathway. Oncol Lett. 16:453–458. 2018.PubMed/NCBI | |
|
Xu S, Wan L, Yin H, Xu H, Zheng W, Shen M, Zhang Z and Pang D: Long noncoding RNA Linc00152 functions as a tumor propellant in pan-cancer. Cell Physiol Biochem. 44:2476–2490. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Feng S, Zhang J, Su W, Bai S, Xiao L, Chen X, Lin J, Reddy RM, Chang AC, Beer DG and Chen G: Overexpression of LINC00152 correlates with poor patient survival and knockdown impairs cell proliferation in lung cancer. Sci Rep. 7:29822017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen M, Liu B, Xiao J, Yang Y and Zhang Y: A novel seven-long non-coding RNA signature predicts survival in early stage lung adenocarcinoma. Oncotarget. 8:14876–14886. 2017.PubMed/NCBI | |
|
Zheng S, Zheng D, Dong C, Jiang J, Xie J, Sun Y and Chen H: Development of a novel prognostic signature of long non-coding RNAs in lung adenocarcinoma. J Cancer Res Clin Oncol. 143:1649–1657. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liu B, Chen Y and Yang J: LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma. Oncotarget. 8:24275–24291. 2017.PubMed/NCBI | |
|
Zhao K, Li Z and Tian H: Twenty-gene-based prognostic model predicts lung adenocarcinoma survival. Onco Targets Ther. 11:3415–3424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shen S, Wei Y, Zhang R, Du M, Duan W, Yang S, Zhao Y, Christiani DC and Chen F: Mutant-allele fraction heterogeneity is associated with non-small cell lung cancer patient survival. Oncol Lett. 15:795–802. 2018.PubMed/NCBI | |
|
Heeke S and Hofman P: Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: Getting ready for prime-time or not? Transl Lung Cancer Res. 7:631–638. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Owada-Ozaki Y, Muto S, Takagi H, Inoue T, Watanabe Y, Fukuhara M, Yamaura T, Okabe N, Matsumura Y, Hasegawa T, et al: Prognostic impact of tumor mutation burden in patients with completely resected non-small cell lung cancer: Brief report. J Thorac Oncol. 13:1217–1221. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, Olaussen KA, Fulton R, Sakashita S, McLeer-Florin A, et al: Tumor mutation burden as a biomarker in resected non-small-cell lung cancer. J Clin Oncol. 36:2995–3006. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sethi G, Shanmugam MK, Arfuso F and Kumar AP: Role of RNF20 in cancer development and progression-a comprehensive review. Biosci Rep. 38(pii): BSR201712872018. View Article : Google Scholar : PubMed/NCBI | |
|
Woodard GA, Jones KD and Jablons DM: Lung cancer staging and prognosis. Lung Cancer Ttreat Res. 170:47–75. 2016. View Article : Google Scholar | |
|
Yang Y, Xie Y and Xian L: Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: A system review and meta-analysis. J Exp Clin Cancer Res. 32:152013. View Article : Google Scholar : PubMed/NCBI | |
|
Gong W, Zhang X, Wu J, Chen L, Li L, Sun J, Lv Y, Wei X, Du Y, Jin H and Dong J: RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: A meta-analysis. Lung Cancer. 75:374–380. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Deng B, Sun Z, Jason W and Yang P: Increased BCAR1 predicts poor outcomes of non-small cell lung cancer in multiple-center patients. Ann Surg Oncol. 20 (Suppl 3):S701–S708. 2013. View Article : Google Scholar : PubMed/NCBI |
